India, June 12 -- Incyte Corp. (INCY) announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz)-a humanized monoclonal antibody targeting PD-1-combined with carboplatin and paclitaxel, have been published in The Lancet. The study focused on adults with inoperable, locally recurrent, or metastatic squamous cell carcinoma of the anal canal (SCAC) who had not previously received systemic chemotherapy.
According to the company, the POD1UM-303/InterAACT2 trial results showed that the study met its primary endpoint by demonstrating a statistically significant improvement in progression-free survival (PFS) in patients with inoperable locally recurrent or metastatic SCAC not previously treated with system...